Yongrong Wu
Overview
Explore the profile of Yongrong Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin F, Long Y, Li M, Cai C, Wu Y, You X, et al.
Heliyon
. 2024 Jul;
10(12):e32914.
PMID: 38994113
Objective: Prostate cancer, marked by a high incidence and mortality rate, presents a significant challenge, especially in the context of castration-resistant prostate cancer (CRPC) with limited treatment options due to...
2.
Ning Y, Wu Y, Zhou Q, Teng Y
Comb Chem High Throughput Screen
. 2023 Jun;
27(6):863-876.
PMID: 37259219
Background: It remains a challenge to effectively treat prostate cancer (PCa) that affects global men's health. It is essential to find a natural alternative drug and explore its antitumor mechanism...
3.
Guan L, Liu Z, Pan G, Zhang B, Wu Y, Gan T, et al.
BMC Gastroenterol
. 2023 Feb;
23(1):44.
PMID: 36814190
Background: Appendicitis is the most common abdominal surgical emergency worldwide, and its burden has been changing. We report the level and trends of appendicitis prevalence, and incidence; and years lived...
4.
Cui X, Wu Y, Wu J, You Z, Xiahou J, Ouyang M
Front Neuroinform
. 2022 Nov;
16:997282.
PMID: 36387584
Music plays an essential role in human life and can act as an expression to evoke human emotions. The diversity of music makes the listener's experience of music appear diverse....
5.
Ouyang G, Pan G, Guan L, Wu Y, Lu W, Qin C, et al.
Liver Int
. 2022 Oct;
42(12):2662-2673.
PMID: 36214561
Background: Hepatitis is a major public health challenge and a leading cause of death worldwide. We aimed to study the cause-specific incidence and temporal trends of acute viral hepatitis (AVH)....
6.
Xu X, Li N, Wu Y, Yan K, Mi Y, Yi N, et al.
Front Pharmacol
. 2022 Oct;
13:951860.
PMID: 36188596
Knee osteoarthritis (KOA), a chronic degenerative disease, is mainly characterized by destruction of articular cartilage and inflammatory reactions. At present, there is a lack of economical and effective clinical treatment....
7.
You X, Wu Y, Li Q, Sheng W, Zhou Q, Fu W
Front Pharmacol
. 2022 Jul;
13:895696.
PMID: 35847007
Prostate cancer (PCa) is an epithelial malignancy of the prostate that currently lacks effective treatment. Traditional Chinese medicine (TCM) can play an anticancer role through regulating the immune system, anti-tumor...
8.
Wu Y, You X, Lin Q, Xiong W, Guo Y, Huang Z, et al.
Front Pharmacol
. 2022 Mar;
12:791269.
PMID: 35342388
Drug resistance is the major cause of increasing mortality in prostate cancer (PCa). Therefore, it an urgent to develop more effective therapeutic agents for PCa treatment. Xihuang pills (XHP) have...
9.
Ouyang G, Wu Y, Liu Z, Lu W, Li S, Hao S, et al.
Medicine (Baltimore)
. 2022 Jan;
100(48):e27870.
PMID: 35049189
Background: Recent randomized controlled trials revealed the combination of gemcitabine and capecitabine (GemCap) regime shows promising efficacy in pancreatic cancer patients. Here, we conducted a meta-analysis to compare the efficacy...
10.
Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, et al.
Cancer Med
. 2022 Jan;
11(5):1357-1370.
PMID: 34989144
Background: Liver cancer is one of the most common cancers worldwide. We aimed to report the burden of liver cancer at the global, regional, and national levels in 204 countries...